Cargando…

MON-443 Periostin Concentrations in Childhood-Onset Craniopharyngioma Patients

Objective: The extracellular matrix protein periostin is highly expressed in adamantinomatous craniopharyngioma-associated fibroblasts. Periostin has been further identified as a novel marker for Non-Alcoholic Fatty Liver Disease (NAFLD). Half of childhood-onset craniopharyngioma patients (CP) with...

Descripción completa

Detalles Bibliográficos
Autores principales: Heinks, Kerstin, De Schutter-Nüsse, Caroline, Boekhoff, S, Bogusz, Agnieszka, Zhu, Jinzhou, Peng, Jungxiang, Muller, Hermann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550905/
http://dx.doi.org/10.1210/js.2019-MON-443
_version_ 1783424290167717888
author Heinks, Kerstin
De Schutter-Nüsse, Caroline
Boekhoff, S
Bogusz, Agnieszka
Zhu, Jinzhou
Peng, Jungxiang
Muller, Hermann
author_facet Heinks, Kerstin
De Schutter-Nüsse, Caroline
Boekhoff, S
Bogusz, Agnieszka
Zhu, Jinzhou
Peng, Jungxiang
Muller, Hermann
author_sort Heinks, Kerstin
collection PubMed
description Objective: The extracellular matrix protein periostin is highly expressed in adamantinomatous craniopharyngioma-associated fibroblasts. Periostin has been further identified as a novel marker for Non-Alcoholic Fatty Liver Disease (NAFLD). Half of childhood-onset craniopharyngioma patients (CP) with hypothalamic syndrome develop NAFLD. We hypothesized that periostin concentration is elevated in biological fluids of CP and associated with pathological hepatic parameters, indicating increased risk for NAFLD. Design: Cross-sectional study on patients with sellar masses (SMP) recruited in the German Craniopharyngioma Registry. Patients: 35 SMP (32 CP, 2 xanthogranuloma, one pilocytic astrocytoma), 3 short-statured patients with isolated growth hormone deficiency (GHD), 5 short-statured patients with normal findings in GH stimulating tests and decreased insulin-like growth factor (IGF)-1 (IGF-1D) and 7 healthy controls. Measurements: Periostin concentrations were measured by Elisa in serum (32 CP, 2 xanthograuloma, 3 GHD, 5 IGF-1D and 7 healthy controls), urine (27 CP, 3 GHD, 5 IGF-1D, 7 healthy controls) and saliva (18 CP, 3 GHD, 3 IGF-1D, 7 healthy controls). Results: Periostin serum, urine and saliva concentrations in CP were similar to concentrations of the other groups. Hypothalamic involvement/hypothalamic lesions, degree of obesity (BMI SDS) as well as hepatic enzymes were not associated with elevated periostin concentrations. Due to low patient numbers with pathological hepatic parameters, missing imaging data on the degree of steatosis hepatis and the lack of histological proof of NAFLD no definitive conclusions can be drawn from measured periostin concentrations in serum. Interestingly, the subgroup of patients with decreased IGF-1 levels showed elevated concentrations of serum periostin when compared with other groups. Conclusions: Periostin concentrations in biological fluids of CP are not associated with known risk factors for NAFLD such as hepatic and metabolic parameters, obesity and hypothalamic lesions. Accordingly, periostin does not seem to be a suitable marker for NAFLD in childhood-onset CP. The association between decreased IGF-1 and increased periostin concentrations should be part of further investigation.
format Online
Article
Text
id pubmed-6550905
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-65509052019-06-13 MON-443 Periostin Concentrations in Childhood-Onset Craniopharyngioma Patients Heinks, Kerstin De Schutter-Nüsse, Caroline Boekhoff, S Bogusz, Agnieszka Zhu, Jinzhou Peng, Jungxiang Muller, Hermann J Endocr Soc Neuroendocrinology and Pituitary Objective: The extracellular matrix protein periostin is highly expressed in adamantinomatous craniopharyngioma-associated fibroblasts. Periostin has been further identified as a novel marker for Non-Alcoholic Fatty Liver Disease (NAFLD). Half of childhood-onset craniopharyngioma patients (CP) with hypothalamic syndrome develop NAFLD. We hypothesized that periostin concentration is elevated in biological fluids of CP and associated with pathological hepatic parameters, indicating increased risk for NAFLD. Design: Cross-sectional study on patients with sellar masses (SMP) recruited in the German Craniopharyngioma Registry. Patients: 35 SMP (32 CP, 2 xanthogranuloma, one pilocytic astrocytoma), 3 short-statured patients with isolated growth hormone deficiency (GHD), 5 short-statured patients with normal findings in GH stimulating tests and decreased insulin-like growth factor (IGF)-1 (IGF-1D) and 7 healthy controls. Measurements: Periostin concentrations were measured by Elisa in serum (32 CP, 2 xanthograuloma, 3 GHD, 5 IGF-1D and 7 healthy controls), urine (27 CP, 3 GHD, 5 IGF-1D, 7 healthy controls) and saliva (18 CP, 3 GHD, 3 IGF-1D, 7 healthy controls). Results: Periostin serum, urine and saliva concentrations in CP were similar to concentrations of the other groups. Hypothalamic involvement/hypothalamic lesions, degree of obesity (BMI SDS) as well as hepatic enzymes were not associated with elevated periostin concentrations. Due to low patient numbers with pathological hepatic parameters, missing imaging data on the degree of steatosis hepatis and the lack of histological proof of NAFLD no definitive conclusions can be drawn from measured periostin concentrations in serum. Interestingly, the subgroup of patients with decreased IGF-1 levels showed elevated concentrations of serum periostin when compared with other groups. Conclusions: Periostin concentrations in biological fluids of CP are not associated with known risk factors for NAFLD such as hepatic and metabolic parameters, obesity and hypothalamic lesions. Accordingly, periostin does not seem to be a suitable marker for NAFLD in childhood-onset CP. The association between decreased IGF-1 and increased periostin concentrations should be part of further investigation. Endocrine Society 2019-04-30 /pmc/articles/PMC6550905/ http://dx.doi.org/10.1210/js.2019-MON-443 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Neuroendocrinology and Pituitary
Heinks, Kerstin
De Schutter-Nüsse, Caroline
Boekhoff, S
Bogusz, Agnieszka
Zhu, Jinzhou
Peng, Jungxiang
Muller, Hermann
MON-443 Periostin Concentrations in Childhood-Onset Craniopharyngioma Patients
title MON-443 Periostin Concentrations in Childhood-Onset Craniopharyngioma Patients
title_full MON-443 Periostin Concentrations in Childhood-Onset Craniopharyngioma Patients
title_fullStr MON-443 Periostin Concentrations in Childhood-Onset Craniopharyngioma Patients
title_full_unstemmed MON-443 Periostin Concentrations in Childhood-Onset Craniopharyngioma Patients
title_short MON-443 Periostin Concentrations in Childhood-Onset Craniopharyngioma Patients
title_sort mon-443 periostin concentrations in childhood-onset craniopharyngioma patients
topic Neuroendocrinology and Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550905/
http://dx.doi.org/10.1210/js.2019-MON-443
work_keys_str_mv AT heinkskerstin mon443periostinconcentrationsinchildhoodonsetcraniopharyngiomapatients
AT deschutternussecaroline mon443periostinconcentrationsinchildhoodonsetcraniopharyngiomapatients
AT boekhoffs mon443periostinconcentrationsinchildhoodonsetcraniopharyngiomapatients
AT boguszagnieszka mon443periostinconcentrationsinchildhoodonsetcraniopharyngiomapatients
AT zhujinzhou mon443periostinconcentrationsinchildhoodonsetcraniopharyngiomapatients
AT pengjungxiang mon443periostinconcentrationsinchildhoodonsetcraniopharyngiomapatients
AT mullerhermann mon443periostinconcentrationsinchildhoodonsetcraniopharyngiomapatients